ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cardiovascular disease

A Heart In Danger

Jane E. Salmon, MD  |  November 1, 2006

Rheumatologists should monitor and aggressively treat cardiac risk factors in patients with lupus and rheumatoid arthritis

Filed under:ConditionsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:atherosclerosisCardiovascular diseaseDiagnostic CriteriaLupusPathogenesisRheumatoid arthritisTreatment

Prednisone or Methotrexate for Pulmonary Sarcoidosis?

Deborah Levenson  |  December 11, 2025

The recently released PREDMETH study results indicate that methotrexate can be considered a real alternative to prednisone for patients with pulmonary sarcoidosis.

Filed under:Biologics/DMARDsConditionsDrug UpdatesOther Rheumatic ConditionsResearch Rheum Tagged with:CorticosteroidsMethotrexateprednisonepulmonary sarcoidosisSarcoidosis

Rethinking Lupus Nephritis: Are Current Approaches & Guidelines off Target?

Mithu Maheswaranathan, MD  |  December 9, 2025

A rheumatologist & lupus expert reviews lupus nephritis treatment, questioning proteinuria cutoffs & ACR guidelines, advocating for newer therapies & end-of-treatment biopsies.

Filed under:Biologics/DMARDsClinical Criteria/GuidelinesConditionsDrug UpdatesGuidanceMeeting ReportsSystemic Lupus Erythematosus Tagged with:belimumabbiopsyCAR-T cell therapyLupus nephritis supplementMycophenolateobinutuzumabProteinuriaSLE Resource Centervoclosporin

Lupus Nephritis: A Serious Manifestation of Systemic Lupus Erythematosus

Graciela S. Alarcón, MD, MPH, MACR  |  December 6, 2025

This review highlights some of the many abstracts on lupus nephritis research presented at ACR Convergence 2025. They demonstrate advances made on early recognition of the condition, as well as offering some hope in terms of achieving better outcomes.

Filed under:ACR ConvergenceConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2025ACR Convergence 2025 - LNLupus nephritis supplementresearch reviews

Workforce Solutions

Mithu Maheswaranathan, MD  |  November 14, 2025

Three experts discussed novel and practical strategies and resources that rheumatology clinics can use to improve the referral process, screening times and patients access to care.

Filed under:ACR ConvergenceMeeting ReportsPractice Support Tagged with:ACR Convergence 2025eConsultPractice ManagementPrimary Care PhysiciansreferralsWorkforce

Advances in Giant Cell Arteritis

Philip Seo, MD, MHS  |  November 14, 2025

Dr. Philip Seo highlights the latest research into the assessment and treatment of giant cell arteritis presented during ACR Convergence 2025.

Filed under:ACR ConvergenceConditionsMeeting ReportsVasculitis Tagged with:AAV FocusRheumACR Convergence 2025ANCA-Associated Vasculitisgiant cell arteritis (GCA)GlucocorticoidsimagingMagnetic resonance imaging (MRI)taperingupadacitinib

Case Reports: Mimics of Polyarteritis Nodosa

Shane Murray, BMBS, RhMSUS, Zhe Ran Duan, MD, PhD, & Daniel DeMizio, MD  |  September 8, 2025

When polyarteritis nodosa isn’t PAN: Two cases of mimics, segmental arterial mediolysis (SAM) & vascular Ehlers-Danlos syndrome (vEDS), are explored.

Filed under:ConditionsVasculitis Tagged with:AAV FocusRheumaneurysmscase reportdifferential diagnosisEhlers-Danlosmimicspolyarteritis nodosasegmental arterial mediolysisvasculopathy

Key Research in Vasculitis Encapsulated

Philip Seo, MD, MHS  |  August 6, 2025

Summaries of selected research abstracts on the assessment & management of systemic vasculitis from ACR Convergence 2024.

Filed under:ACR ConvergenceConditionsMeeting ReportsResearch RheumVasculitis Tagged with:AAV FocusRheumACR Convergence 2024DADA2eosinophilic granulomatosis with polyangiitis (EGPA)Giant Cell ArteritisGlucocorticoidsgranulomatosis with polyangiitisIgG4 related diseaseinebilizumabInterleukinJAK inhibitormepolizumabupadacitinibVasculitis

JAK Inhibitors 101

Jason Liebowitz, MD, FACR  |  July 28, 2025

Experts provided an in-depth review of Janus kinase (JAK) inhibitors, discussing the latest research on their use in the treatment of specific rheumatic conditions, the risks associated with them and more.

Filed under:Biologics/DMARDsConditionsDrug UpdatesEULAR/OtherGuidanceMeeting Reports Tagged with:EULAR 2025JAK inhibitorsJanus Kinase Inhibitors

Finding the Panacea: The Management of Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  July 16, 2025

In a session at EULAR 2025, Dr. Laura Coates discussed the management of PsA, providing insights into the current research and when clinicians may want to consider prescribing specific medications.

Filed under:ConditionsEULAR/OtherGuidanceMeeting ReportsPsoriatic Arthritis Tagged with:Axial Psoriatic Arthritis (axPsA)EULAR 2025PsAPsA Resource Centerpsoriatic arthritisskin

  • « Previous Page
  • 1
  • …
  • 36
  • 37
  • 38
  • 39
  • 40
  • …
  • 66
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences